TLR-4 and Sustained Calcium Agonists Synergistically Produce Eicosanoids Independent of Protein Synthesis in RAW264.7 Cells*

Matthew W. Buczynski, Daren L. Stephens, Rebecca C. Bowers-Gentry, Andrej Grkovich, Raymond A. Deems, and Edward A. Dennis1

From the Department of Chemistry and Biochemistry and Department of Pharmacology and School of Medicine, University of California, San Diego, La Jolla, California 92093

Arachidonic acid (AA)2 and its eicosanoid metabolites are associated with a variety of different physiological systems, including the central nervous, cardiovascular, gastrointestinal, genitourinary, respiratory, and immune systems. Eicosanoids are formed when phospholipase A2 (PLA2) action liberates AA from the sn-2 position of membrane phospholipids (1, 2). Free AA is then converted into potent bioactive mediators by the action of the various cyclooxygenases (COX), lipoxygenases (LO), and cytochrome P450s. The eicosanoid production cascade often works in a nonlinear fashion, with multiple enzymes creating a single product and multiple products acting as a substrate for a single enzyme. COX activity produces prostaglandins (PG) and hydroxyeicosatetraenoic acids (HETEs) (3, 4), whereas lipoxygenases can create leukotrienes (LT), HETEs, and lipoxins (5–8). Cytochrome P450s catalyze the production of HETEs and epoxy-eicosatetraenoic acids, as well as ω-oxidation of various eicosanoids (9). Other enzymes can further act on eicosanoids by catalyzing hydration, dehydration, and β-oxidation reactions (10). Eicosanoid-producing enzymes and their biological receptors are differentially expressed among various cell and tissue types, enhancing signaling specificity (11). This is illustrated by Fitzgerald and co-workers (12), who demonstrated that decreased vascular PGE2 release leads to increased endothelial PGI2 production, impeding the development of atherogenesis.

Early studies of eicosanoid identification and quantification focused on enzyme-linked immunosorbent assays (13, 14). This method is reliable for measuring relative changes in the level of an individual eicosanoid; however, specificity deficiencies and cost limitations reduce their usefulness for studying an array of eicosanoids. Gas chromatography/mass spectrometry (GC/MS) methods were developed that greatly improved upon these limitations (15) and allowed the simultaneous analysis of multiple eicosanoids. One drawback of the GC/MS method is the requirement that eicosanoids be chemically derivatized in
order to be volatile for GC. Although a wide variety of derivatization methods has been developed increasing the number of eicosanoids that can be effectively detected, a single derivatization method is not suitable to prepare all of the diverse eicosanoids for GC volatilization. Furthermore, some eicosanoids are ill-suited for any gas phase analysis (16), making GC/MS insufficient for analysis of the entire class.

The development of electrospray ionization (ESI) eliminated the requirement for derivatization by directly ionizing eicosanoids in biological samples. The carboxylate moiety, a prevalent eicosanoid structural feature, readily ionizes in mass spectrometric analysis using ESI. By coupling ESI with triple quadrupole mass spectrometry, eicosanoids can be ionized, and their molecular precursor ion \([M - H]^-\) can be subjected to collision-induced decomposition to produce a series of distinct product ion fragments. A set of precursor/product ion pairs can be analyzed in a single MS analysis using multiple reaction monitoring (MRM) that, when coupled with high performance liquid chromatography retention times, will uniquely identify a majority of the eicosanoids. ESI-MRM was first employed in this field by Isakson and co-workers in 1996 (17) to quantitate 14 eicosanoids directly from a biological sample. In 2002 the resolving power of LC was coupled with the sensitivity of ESI-MRM to study five eicosanoids from LPS-stimulated synovial cells (18). Recently, Shimizu and co-workers (19) have developed a high throughput method that can detect and quantitate 18 different eicosanoids from biological samples.

These methods detected a limited subset of eicosanoids that was selected based on previous experiments with a given cell type or disease model. However, more than a hundred unique eicosanoids have been discovered to date, with many having unique biological activities. A thorough investigation of these biological processes requires one to simultaneously analyze a large number of eicosanoids in a single analysis. Analogous to gene array analyses in the genomics field, we have created a library of MS/MS spectra for a large number of eicosanoids and have defined a set of MRM precursor/product ion pairs and an LC system that allows for the identification and quantitation of a large number of these compounds in a single LC/MS/MS run. By using this less biased approach, it should be possible to identify novel eicosanoid signaling networks and efficiently translate this methodology across a diverse array of biological models.

This methodology has now been applied to the study of RAW264.7 macrophages. Macrophages express a number of Toll-like receptors (TLR) (20). TLRs comprise a family of receptors that recognize specific structures of microbial pathogens, leading to the induction of numerous pro-inflammatory cytokines, COX-2 up-regulation, and delayed eicosanoid release. Macrophages also express receptors that can induce rapid changes in intracellular \(Ca^{2+}\) levels. \(Ca^{2+}\) affects a number of processes within the macrophage and specifically binds to group IVA cytosolic PLA\(_2\) (cPLA\(_2\)) and 5-LO promoting their translocation to the membrane phospholipid surface (1, 5). Platelet-activating factor (PAF) and UDP signal through specific G protein-coupled receptors (GPCR) that create a transient \(Ca^{2+}\) spike (21–23). Nonreceptor-mediated ionophores such as ionomycin, and purinergic receptor activation by high levels of adenosine triphosphate (ATP), can produce sustained changes in intracellular \(Ca^{2+}\) levels that induce eicosanoid production (21, 23, 24). Furthermore, the response to \(Ca^{2+}\) agonists has been shown to be synergistically increased by priming cells with a 60-min dose of a TLR activator (21, 25–29), producing more eicosanoid release than the additive amount of TLR and \(Ca^{2+}\) stimulation alone. Here we employed LC/MS/MS methodology to specifically investigate these mechanisms of eicosanoid generation, identifying two distinct eicosanoid profiles. We further investigated the synergy between TLR and \(Ca^{2+}\) agonists, and we have elucidated details of the mechanism for endotoxin priming and stimulation of eicosanoid production.

**EXPERIMENTAL PROCEDURES**

**Materials**—RAW264.7 murine macrophage cells were purchased from American Type Culture Collection (Manassas, VA). LC-grade solvents were purchased from EMD Biosciences. Strata-X solid phase extraction columns were purchased from Phenomenex (Torrance, CA). Phosphate-buffered saline (PBS) was purchased from VWR. Dulbecco’s modified Eagle’s medium, fetal bovine serum, and broad range DNA Quant-Kit was purchased from Invitrogen. Lipopolysaccharide (LPS), zymosan, ionomycin, ATP, UDP, ETG, and bovine serum albumin were purchased from Sigma. The TLR agonists N-palmitoyl-S-[2,3-bis(palmitoyloxy)-2(2S,2S)-propyl]-Cys-[S]-Ser-[S]-Lys (4) trihydrochloride (Pam3SCK4), heat-killed *Listeria monocytogenes* (HKL), lipoteichoic acid from *Staphylococcus aureus* (LTA), polyniosine-polycytidylic acid (poly[I-C]), flagellin from *Salmonella typhimurium* (flagellin), S-(2,3-bis(palmitoyloxypropyl)-Cys-Gly-Asp-Pro-Lys-His-Pro-Ser-Phe (FSL-1), imiquimod, and synthetic oligodeoxynucleotide 1826, 5’-TCCATGACGTCTCTGAC-GTT-3’ (ODN1826), were purchased from InvivoGen (San Diego, CA). Kdo\(_2\)-lipid A and 1-palmitoyl-2-archachonyl phosphatidylcholine was obtained from Avanti Polar Lipids (Alabaster, AL). L-1-Palmitoyl, 2-[\(^{14}\)C]arachidonyl phosphatidylcholine was purchased from PerkinElmer Life Sciences. All eicosanoids, PAF, and indomethacin were purchased from Cayman Chemicals (Ann Arbor, MI). The cPLA\(_{2\gamma}\), p-cPLA\(_{2\gamma}\) (Ser-505), anti-rabbit IgG-HRP, and anti-mouse IgG-HRP antibodies were purchased from Cell Signaling (Beverly, MA). The 5-LO, COX-1, COX-2 antibodies, and 5-LO blocking peptide were purchased from AbCam (Cambridge, MA). The glyceraldehyde-3-phosphate dehydrogenase antibody was purchased from HyTest (Turku, Finland). The anti-goat IgG-HRP antibody was purchased from Sigma. Actinomycin D (ActD), cycloheximide (CHX), and BAY 11-7082 (BAY) were purchased from Biomol (Plymouth Meeting, PA). 6-Amino-4-(4-phenoxypyphenylamino) quinazoline was purchased from Calbiochem. Pyrrophenone was a kind gift from Dr. Kohji Hana-saki (Shionogi Research Laboratories). Zileuton was a kind gift from Prof. Robert C. Murphy (University of Colorado). All other reagents were reagent grade or better.

**Cell Culture and Stimulation Protocol**—The RAW264.7 mouse murine macrophage cells were cultured in Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum and 100 units/ml penicillin/streptomycin at 37 °C in a humidified 5%
Synergistic Eicosanoid Production in Macrophages

CO₂ atmosphere. Cells were plated in 6-well culture plates with 2 ml of media (2 × 10⁶ cells for short term studies, 1 × 10⁶ cells for long term studies) and allowed to adhere for 24 h, the media were replaced with 1.8 ml of serum-free media and after 1 h were stimulated. Short term stimuli were added for 10 min at the following doses: PAF (100 nm), UDP (25 μM), ionomycin (1 μM), ATP (2 mm). Long term stimuli were added for 12 h at the following doses: Pam3SCK4 (1 μg/ml), HKLM (10⁸ cells/ml), LTA (1 μg/ml), poly(I-C) (50 μg/ml), LPS (100 ng/ml), Kdo₂-lipid A (100 ng/ml), flagellin (50 ng/ml), FSL-1 (1 μg/ml), zymosan (500 ng/ml), imiquimod (5 μg/ml), gardiquimod (1 μg/ml), ODN1826 (1 μM). In priming experiments, cells were incubated with Kdo₂-lipid A (100 ng/ml) for 50 min, followed by the addition of vehicle or short term agonist (PAF, UDP, ionomycin, ATP) for 10 min.

Sample Preparation—The media were analyzed for extracellular eicosanoid release. After stimulation, the entire 1.8 ml of media was removed, and each sample was supplemented with 100 μl of internal standards (100 pg/μl, EtOH) and 100 μl of EtOH to bring the total volume of EtOH to 10% by volume. Samples were centrifuged for 5 min at 3000 rpm to remove cellular debris, and then purified. Intracellular eicosanoids were analyzed in the remaining adherent cells by scraping them into 500 μl of MeOH and then adding 1000 μl of PBS and 10 μl of internal standards.

Eicosanoids were extracted using Strata-X SPE columns. Columns were washed with 3 ml of MeOH and then 3 ml of H₂O. After applying the sample, the columns were washed with 10% MeOH, and the eicosanoids were then eluted with 1 ml of MeOH. The eluant was dried under vacuum and redissolved in 100 μl of LC solvent A (water/acetonitrile/formic acid (63:37:0.02; v/v/v)) for LC/MS/MS analysis.

It was experimentally determined that intracellular samples contained 1–2% of the extracellular media. The remaining 2% of extracellular eicosanoids were not removed with a wash step because it was determined that the process of washing the cells stimulated eicosanoid release. Measurements approaching 2% of the extracellular eicosanoid level were assumed to be due to media carryover.

Cell Quantitation—Eicosanoid levels were normalized to cell number using DNA quantitation. After the extracellular media were removed, the cells were scraped in 500 μl of PBS and stored at 4 °C for DNA quantitation using the Broad Range DNA Quant-Kit according to the manufacturer’s instructions. Intracellular experiments required scraping cells into pure MeOH for eicosanoid analysis. Because MeOH significantly affected the DNA quantitation assay, we determined DNA levels from a separate well in these experiments. A conversion factor of 664 cells per ng of DNA was experimentally determined and normalized using the Bio-Rad Protein Assay (Bio-Rad). 0.15 μg of total protein was loaded onto 4–12% Bis-Tris SDS-polyacrylamide gels, electrophoresed, and transferred onto a nitrocellulose membrane.

For COX-1 or COX-2, the membrane was blocked with 3% bovine serum albumin, 1% casein in Tris-buffered saline buffer containing 0.05% Tween 20 for 1 h, incubated with either 1:100 COX-1 (Cayman Chemicals, Ann Arbor, MI) or 1:100 COX-2 (Cayman Chemicals, Ann Arbor, MI) specific antibody overnight, washed three times in Tris-buffered saline containing 0.05% Tween 20, incubated with 1:2000 anti-rabbit biotinylated IgG secondary antibody (Vector Laboratories, Burlingame, CA) for 30 min, washed three times, and incubated with 1:5000 streptavidin/HRP-conjugated antibody (Vector Laboratories, Burlingame, CA) for 30 min.

For all other proteins, the membrane was blocked with 5% milk protein in PBS buffer containing 0.1% Tween 20 for 1 h, incubated with 1:1000 of the appropriate specific antibody overnight, washed three times in PBS containing 0.1% Tween 20, and incubated with 1:1000 of the appropriate secondary antibody for 1 h. All membranes were washed three times before development using the Western Lightning ECL kit (Amersham Biosciences).

Group IVA PLA₂ Assay—Group IVA ePLA₂ activity was determined by measuring the release of free [14C]arachidonic acid. Final assay conditions were as follows: 100 mM HEPES, pH 7.5, 80 μM CaCl₂, 0.1 mg/ml bovine serum albumin, 2 mM dithiothreitol, 400 μM Triton X-100, 3 μM phosphatidylinositol 4,5-bisphosphate (PIP₃), and 97 μM 1-palmitoyl-2-ara-chidonoylphosphatidylcholine with 100,000 cpm 1-1-palmitoyl, 2-[14C]arachidonoyl phosphatidylcholine. Radiolabeled free fatty acid was separated from the phospholipid substrate via our...
modified Dole fatty acid extraction procedure (31, 32) and counted in a Packard 1600TR (Packard Instruments).

RESULTS

Eicosanoid Production during Long Term TLR Activation—We examined two factors that modulate the release of eicosanoids in macrophages, TLR activation and changes in intracellular Ca^{2+} levels. TLR activation initiates many changes in the cell, including the induction of gene expression, changes in protein levels, and changes in protein phosphorylation levels. We have measured changes in eicosanoid release when RAW264.7 cells were activated by long term exposure to 12 different TLR agonists, which leads to the induction of a number of pro-inflammatory proteins through the transcription factor NF-κB.

We began by qualitatively analyzing the eicosanoids released into the extracellular media of RAW264.7 macrophages when challenged with one of 12 TLR agonists (Table 1). A signal was judged to be significant, and the eicosanoid present (+ in shaded cell), if the signal area was three times the noise three standard deviation level. A minus sign indicates that the signal was below this level. In these experiments, we screened all 64 eicosanoids listed in supplemental Table 1. In all, eight different TLRs were examined. We began with Kdo₂-lipid A, a nearly homogeneous LPS sub-structure with endotoxin activity equal to that of native LPS. Kdo₂-lipid A is a chemically defined LPS, consisting of lipid A and an attached 3-keto-D-manno-octulosonic acid disaccharide. The highly variable carbohydrate chains that are present on natural LPS have been removed, and the lipid A portion of the molecule has a fatty acid composition that is greater than 90% homogeneous. Kdo₂-lipid A binds to and activates only the TLR-4 receptor (33). Although we looked for each of the 64 different eicosanoids, when RAW264.7 cells were challenged with Kdo₂-lipid A for 12 h, only compounds produced by the COX pathway were detected. COX-derived PGF\(_{2α}\), PGE\(_{2}\), and PGD\(_{2}\) were released, and prostaglandin PGD\(_{2}\) dehydration metabolites PGJ\(_{2}\), 15-deoxy-\(\Delta^{12,14}\)-PGD\(_{2}\) (15d PGD\(_{2}\)), and 15-deoxy-\(\Delta^{12,14}\)-PGJ\(_{2}\) (15d PGJ\(_{2}\)) were also detected. Additionally, oxidation metabolites 13,14-dihydro-15-keto PGF\(_{2α}\)(dhk PGF\(_{2α}\), 13,14-dihydro-15-keto PGE\(_{2}\)(dhk PGE\(_{2}\)), and 13,14-dihydro-15-keto PGD\(_{2α}\)(dhk PGD\(_{2}\)) were identified. The potential side products of COX action on AA,
11-HETE and 15-HETE were also detected. Their formation was completely inhibited by the COX inhibitor indomethacin (data not shown), confirming that they are being generated by the COX enzymes.

The eicosanoid release profiles of TLRs 1–7 and TLR-9, when stimulated with the appropriate receptor-specific agonists for 12 h, were the same as that seen with Kdo₂-lipid A. The one exception was that in response to the TLR-5 agonist, flagellin, dhk PGF₂α, dhk PGE₂, and dhk PGF₂α were not detected. In these experiments, we employed levels of agonist within the range suggested by InvivoGen, but we did not attempt to maximize the response. Therefore, the absolute levels of the response do not necessarily represent maximal responses, and only the relative eicosanoid profiles should be compared.

We then narrowed our focus and repeated these experiments quantitating only those compounds detected in the screen. This examination of long term Kdo₂-lipid A stimulation of TLR-4 showed that PGD₂ was the most abundant eicosanoid released (Fig. 1). Although not as substantial as PGD₂ levels, PGE₂ and PGF₂α levels were also significantly increased. Metabolites of PGD₂ resulting from a single dehydration (PGJ₂ and 15d PGD₂) were higher than the double dehydration product 15d PGJ₂. Activation of TLR-1, -2, -4, -6, -7, and -9 all produced significant levels of PGs, releasing greater than 70 ng/1 × 10⁶ cells of PGD₂ in 12 h, whereas TLR-3 activation by poly(I:C) only induced a moderate activation (9 ng/1 × 10⁶ cells PGD₂). Although each of these TLR-specific agonists produced different absolute levels of PGs, none altered the relative eicosanoid profile from the one induced by Kdo₂-lipid A. Flagellin, the TLR-5 agonist, did not lead to an increase in eicosanoid production over control levels under the conditions employed in RAW264.7 cells.

Eicosanoid Production during Short Term Ca²⁺ Agonist Activation—Eicosanoid release is also regulated by increasing intracellular Ca²⁺ levels, which facilitate the translocation of eicosanoid-producing enzymes, such as cPLA₂ and 5-LO, to the phospholipid membrane (1, 5) where they can actively generate eicosanoid metabolites. Ca²⁺ fluxes can occur in two distinct modes (21, 23). The release of intracellular Ca²⁺ stores causes a transient spike, which quickly returns to near basal levels, whereas changes in the permeability of the plasma membrane create a sustained Ca²⁺ elevation from the influx of extracellular Ca²⁺. Both of these Ca²⁺ changes occur within seconds of activation. In these studies, four short term stimuli that modified Ca²⁺ levels were examined. PAF and UDP stimulate GPCRs and give rise to a transient Ca²⁺ spike (21, 23), whereas ionomycin and ATP produce sustained increases in Ca²⁺ levels.

The qualitative analysis of PAF and UDP stimulation are shown in Table 1. Following a 10-min stimulation with PAF or UDP, COX-derived PGF₂α, PGE₂, PGD₂, 11-HETE, and 15-HETE were released, and PGD₂ dehydration metabolites PGJ₂ and 15d PGD₂ were detected (Table 1). 15d PGJ₂ and the three dhk PGs were not detected. 15d PGJ₂ was presumably not detected because it requires two separate dehydration steps, which require a longer period of time to occur; even after 60 min of Kdo₂-lipid A stimulation, 15d PGJ₂ was not detected. Likewise, PG breakdown into dhk PGF₂α, dhk PGE₂, and dhk
PGD₂ requires an oxidation and a reduction, and these products were not detected. Again, none of the other 64 eicosanoids were detected. The quantitative analysis demonstrated that the foremost eicosanoids released in these pathways were PGD₂ and AA (Fig. 2). The PGD₂ levels were between 0.3 ng/1 × 10⁶ cells for PAF and 0.8 ng/1 × 10⁶ cells for UDP. To confirm that extracellular Ca²⁺ is not required for PAF- and UDP-stimulated eicosanoid production, these experiments were performed in the presence of 2 mM EGTA (data not shown). The level of eicosanoid release was unaffected by the removal of extracellular calcium using EGTA, confirming that intracellular calcium stores play a primary role in activating eicosanoid production in response to these two agonists. This supports data by Asmis et al. (21), who demonstrated that the calcium spike generated by PAF in murine macrophages does not require extracellular Ca²⁺.

Millimolar concentrations of ATP (23), which activate both P2Y and P2X purinergic receptors, and ionomycin (21), a Ca²⁺ ionophore, both produce sustained Ca²⁺ levels in the cell in addition to inducing a transient Ca²⁺ spike like PAF and UDP. The qualitative screen of RAW264.7 cells challenged by either 2 mM ATP or ionomycin showed that these agonists were capable of generating every eicosanoid produced by PAF or UDP stimulation, and in addition activated the 5-LO pathway. Significant levels of 5-HETE, LTC₄, and its heat-induced isomer 11t-LTC₄ were detected. Although ionomycin produced 2 ng/1 × 10⁶ cells of PGD₂ and less than 0.5 ng/1 × 10⁶ cells of the LTC₄s, ATP stimulation produced 2.5 ng/1 × 10⁶ cells of both LTC₄ and PGD₂, LTC₄, 11t-LTC₄, and 5-HETE production was completely inhibited by the 5-LO inhibitor zileuton (data not shown). Furthermore, when 2 mM EGTA was added extracellularly, it completely blocked the production of 5-LO products without significantly affecting COX activity (data not shown), confirming the role of a sustained Ca²⁺ influx in the activation of this pathway. It also demonstrated that the transient spike of Ca²⁺ from the internal stores was insufficient for this activation.

This is significantly less than the levels of PGs seen in the long term stimulations. Presumably, 12 h of TLR activation allows for more time to release AA and up-regulate eicosanoid-producing proteins such as COX-2. For comparison, a 60-min stimulation of Kdo₂-lipid A produced a similar profile to UDP and PAF, generating all of the eicosanoids produced by long term Kdo₂-lipid A except 15d PGJ₂, dhk PGF₂α, dhk PGE₂, and dhk PGD₂. It should be noted that the PGD₂ level at 60 min represents a 10-fold activation over control and although this is larger than any of the Ca²⁺ agonists, it pales in comparison to the several hundredfold activation seen in long term TLR stimulations.

Spatial and Time Dependence of Eicosanoid Production—The analysis of 16 agonists showed that only millimolar ATP or ionomycin exhibited significant differences in the eicosanoid profile, presumably because of the sustained elevation of Ca²⁺.

To explore the nature of these differences, we chose to compare the eicosanoid secretion and degradation over time between short term purinergic activation with ATP and the long term activation with the TLR-4-specific agonist Kdo₂-lipid A. In doing so, we also compared the levels of secreted eicosanoids to their levels inside the cell.

Kdo₂-lipid A stimulation caused intracellular AA levels to rise dramatically, peaking at 1 h and returning to basal levels by 4 h (Fig. 3); extracellular AA followed the same temporal release pattern. COX-derived 11-HETE, but not lipoxygenase derived 5-HETE, was produced in response to Kdo₂-lipid A, peaking at 1 h and slowly returned to basal levels by 12 h. PGF₂α and PGE₂ were released into the extracellular media at a constant rate over 24 h. Extracellular PGD₂, however, increases until 8 h and then began to slowly decline. This decline appears to be due in large part to increases in PGD₂ metabolites PGJ₂, 15d PGD₂, and 15d PGI₂. Significantly elevated levels of PGI₂ were detected after 2 h of stimulation, 15d PGD₂ after 4 h, and 15d PGI₂ after 8 h. The sum of the levels of PGD₂ and its dehydrogenation metabolites continue to increase similar to PGE₂ and PGF₂α, PGs and their metabolites were not detected intracellularly during the 24-h stimulation period.

ATP activation of purinergic receptors created a sustained Ca²⁺ influx and rapid production of eicosanoids by RAW264.7 cells (Fig. 4). Intracellular AA levels peaked during the first 5
inside the cell at 5 min, but by 10 min these metabolites were detected only in the extracellular media.

Synergy between TLR and Ca\(^{2+}\) Activations—Individually, both Kdo\(_2\)-lipid A and Ca\(^{2+}\) agonists can stimulate eicosanoid production in macrophage cells. Previous work has also demonstrated that the level of eicosanoid release can be modulated by adding these agonists together (21, 27–29). Specifically, Aderem et al. (25, 26) showed that adding the TLR-4 agonist LPS for 60 min primed murine macrophages for enhanced eicosanoid release by Ca\(^{2+}\) agonists.

We studied RAW264.7 cells stimulated with Kdo2-lipid A and Ca\(^{2+}\) agonists to determine whether these pathways were overlapping, additive, or synergistic in activating eicosanoid production. To identify the nature of interaction between activation pathways, we calculated a synergistic activation ratio (Equation 1),

\[
\text{Synergistic activation} = \frac{[\text{KDO} + \text{Ca}\(^{2+}\) agonist]}{[\text{KDO}] + [\text{Ca}\(^{2+}\) agonist]} \quad (\text{Eq. 1})
\]

where [KDO] is the quantity of eicosanoid produced by KDO alone, [Ca\(^{2+}\) agonist] is the quantity of the eicosanoid produced by the Ca\(^{2+}\) agonist alone, and [KDO + Ca\(^{2+}\) agonist] is the quantity of the eicosanoid produced by stimulation with both agonists. If the agonists act on separate independent pathways, the eicosanoid production would be additive, and the synergistic activation ratio would be 1. If the two agonists activate the same pathway, their outputs would overlap, and the maximum combined output would not be greater that that of either agonist alone. In this case, the ratio would be less than the sum of each pathway separately and would drop below 1. Finally, if these agonists combine to synergistically generate more eicosanoids than the sum of the individual pathways, the activation ratio would be greater than 1 and indicate a synergistic activation.

To this end, RAW264.7 cells were stimulated with Kdo2-lipid A for 50 min followed with a 10-min dose of one of four Ca\(^{2+}\) agonists: PAF, UDP, ionomycin, or ATP. The synergistic activation ratios are presented in Fig. 5. Within experimental error, the ratios for the PGs in PAF and UDP were 1. The only exception was that the 11-HETE was elevated with UDP. In contrast,
Kdo₂-lipid A enhanced ionomycin-stimulated LTC⁴ and AA release by about 8-fold and ATP release of these metabolites by about 3-fold. PG release, however, was not enhanced by priming by either ATP or ionomycin. Again, 11-HETE was the exception, showing some enhanced release that was midway between the 5-LO products and the PGs.

Activation of the TLR-4 receptor is known to activate NF-kB-induced protein synthesis, particularly COX-2, and this has long been thought to be the mechanism that primes macrophages for enhanced eicosanoid production (28, 29, 34). To examine this possibility, protein levels of cPLA₂, COX-1, COX-2, 5-LO, and 5-LO-activating protein (FLAP) were assessed by Western blot, and did not noticeably change during the 1st h of Kdo₂-lipid A stimulation (Fig. 6A). The levels of cPLA₂ phosphorylated at serine 505 (p-cPLA₂ (Ser-505)), which have been reported to modulate protein activity within the cell (34), also did not change significantly. Cell lysates were further analyzed for cPLA₂ activity with our in vitro assay (Fig. 6B). This assay measures activity under controlled conditions suitable for cPLA₂. We did not detect a significant change in the level of cPLA₂ activity following stimulation with either Kdo₂-lipid A or ATP. Because both the level of protein, detected by Western blot, and the level of cPLA₂ activity, analyzed by in vitro assay, did not change, it appears that both stimuli lead to activation of the pre-existing cPLA₂ but do not increase the level of the enzyme or its phosphorylation state.

This does not eliminate protein synthesis as a mechanism for eicosanoid production by TLR activation during the 1st h. In fact, Kdo₂-lipid A activation of TLR-4 directly induced PG synthesis during the 1st h was inhibited by ActD and CHX, which block the transcription and translation of cellular proteins, respectively (Fig. 7A). Inhibition of NF-kB with BAY also reduced PG synthesis by 60–90%, implicating this transcription factor in the production of protein required for eicosanoid release in the 1st h of stimulation. On the other hand, ATP stimulation of the purinergic receptors was only slightly blunted (10–30% inhibition) by these inhibitors (Fig. 7B), indicating that little or no de novo protein synthesis is required for the short term ATP response and that the constitutive enzyme levels are sufficient to produce these eicosanoid levels.

To determine whether protein synthesis was required for the synergistic enhancement of ATP-induced eicosanoid synthesis, RAW264.7 cells were stimulated with Kdo₂-lipid A for 50 min and followed with a 10-min dose of ATP in the presence of three inhibitors: ActD, CHX, and BAY (Fig. 8). As expected, these inhibitors reduced the absolute eicosanoid levels produced by combined Kdo₂-lipid A and ATP stimulation. Interestingly, the inhibition of protein synthesis did not appear to inhibit Kdo₂-lipid A synergistic activation of leukotriene or AA release. Furthermore, direct inhibition of NF-kB activity by BAY also did not affect the synergy between these pathways. To help confirm this finding, a second inhibitor of NF-kB activation, 6-amino-4-(4-phenoxypyphenylethylamino) quinazoline, was tested. At a 50 nM dose, this compound did not affect Kdo₂-lipid A and ATP synergy (data not shown). Taken together, this demonstrates that, although inhibitors of protein synthesis blocked Kdo₂-lipid A-stimulated eicosanoid release and blunted ATP-stimu-
lated release, they did not prevent Kdo2-lipid A from priming for enhanced ATP-stimulated eicosanoid release.

**DISCUSSION**

**Eicosanoid Profiles in RAW264.7 Cells—**Macrophages express a large number of distinct TLRs, G protein-coupled receptors, and purinergic receptors. When stimulated, these receptors activate cPLA₂ to liberate AA from membrane phospholipids and generate an eicosanoid response by distinctly different pathways. It was anticipated that by using a diverse array of macrophage stimuli, a number of different eicosanoid profiles would be generated that could indicate the presence of agonist-specific responses. To test this hypothesis, we examined the eicosanoid profiles of RAW264.7 cells stimulated with 16 different agonists.

We found that 14 of the 16 agonists produced the same eicosanoid profile. This profile was dominated by COX products, and by far the largest eicosanoid produced was PGD₂ and its dehydration products PGJ₂, 15d-PGJ₂, and 15d-PGD₂. For long term TLR-4 stimulation, this result is consistent with the observations that the levels of COX-2 dramatically increase over this time period, whereas at the same time 5-LO activity is impaired by subsequent nitric oxide production.

It was surprising that the GPCR agonists UDP and PAF exhibited the same profile as TLR agonists because they induce a transient Ca²⁺ spike that activates eicosanoid synthesis within 10 min, well before gene expression and protein synthesis could significantly alter protein levels. Thus, in contrast GPCR agonists should induce eicosanoid synthesis via basally expressed enzymes, which include 5-LO and relatively small amounts of COX. Yet these two agonists induced similar COX-dependent PGD₂ dominated profiles as the TLRs.

The uniformity of the eicosanoid profile in response to these agonists was particularly striking in light of the fact that macrophages obtained from in vivo sources do yield different eicosanoid profiles, as shown by studies that modulate diet (12, 35) and studies in which different methods of macrophage elicitation are employed (19). Furthermore, a comparative study of human atherosclerotic plaques (36) showed that macrophages in unstable plaques have a significantly higher ratio of PGE₂ to PGD₂ synthase than stable plaque macrophages. In this study, plaque stability was attributed to changes in the PGE₂ and PGD₂ synthase levels. The obvious difference between in vivo macrophages and the RAW264.7 cells is that the differentiation process occurs in different environments. Thus, it is possible that the eicosanoid profile was set during monocyte to macrophage differentiation when the RAW264.7 cell line was first generated.

Only one of the receptor-mediated responses investigated, purinergic activation by millimolar levels of ATP, produced a different eicosanoid profile in RAW264.7 cells. In addition to producing COX-derived eicosanoids previously detected from other short term agonists, ATP activated the 5-LO pathway leading to the production of LTC₄. ATP can activate both the
P2Y GPCRs to produce a transient Ca²⁺ spike and P2X cation channels to generate sustained elevated Ca²⁺ levels (23). However, of all the purinergic receptors, only the P2X₇ requires millimolar levels of ATP for activation (37, 38). This receptor is expressed and functional in RAW264.7 cells, and Balboa et al. (24) have shown that this receptor is responsible for the majority of AA-derived metabolite release in response to 2 mM ATP stimulation in murine macrophages. Peripheral tissue cells contain millimolar levels of ATP in the cytosol, and release cytosolic ATP during cellular stress and nonphysiological necrosis (39, 40).

The eicosanoid profile generated by ATP stimulation was also seen with ionomycin stimulation. Ionomycin is a Ca²⁺ ionophore that also creates a sustained Ca²⁺ mobilization in murine macrophage cells (21). In both cases, the emergence of 5-LO products was accompanied by higher levels (3–4-fold) of PG release when compared with PAF and UDP. In the case of ATP, the 5-LO products were produced in equivalent amounts to the PGs. Thus, ATP stimulation not only turns on the 5-LO pathway but also enhances the total eicosanoid production. This response is presumably because of the extended elevated Ca²⁺ levels, which are required for 5-LO activity in this model. These levels would keep cPLA₂ at the membrane longer and would last long enough to see the activation of the 5-LO.

**Intracellular Eicosanoid Levels**—During these studies, we have also examined the eicosanoid levels inside the cell. Kdo₂-lipid A induced an intracellular AA release, which peaked at 60 min and receded as extracellular prostaglandin levels began to rise. The AA inside the cell was ~4 times greater than the amount detected outside. Given the large difference between the volume of the cell and volume of extracellular media, the intracellular concentration of AA would be significant. 11-HETE was also detected inside the cell at a level roughly equal to the extracellular level. These findings confirm the observations of Balsinde and co-workers (41), who also saw increases in intracellular AA-derived compounds following [³H]AA labeling of phospholipids and stimulation of P388D₁ murine macrophages. Significant levels of prostaglandins and their metabolites were not detected intracellularly during long term Kdo₂-lipid A stimulation.

Similar results were observed for the short term Ca²⁺-based stimulation. Within 5 min of stimulation, ATP generated a spike of free AA that dissipated by 10 min. The AA peak coincided with the burst of PGs, LTs and HETEs that were also released in the first 5 min of ATP stimulation. Similar to Kdo₂-lipid A, AA spiked inside the cell ~4 times higher than secreted levels. In addition to AA, small but detectable levels of PGs and LT could be detected intracellularly at 5 min after stimulation with ATP. By 10 min, eicosanoid levels returned to those found in the controls. Taken together, this suggests that the eicosanoids do not build up in RAW264.7 cells but instead are rapidly secreted.
Synergistic Eicosanoid Production in Macrophages

It has been reported that the PGD<sub>2</sub> metabolite 15d PGJ<sub>2</sub> could be detected intracellularly using a monoclonal antibody (10), and suggested that it initiates an anti-inflammatory response through the transcription factor PPAR-α. We were unable to detect significant levels of 15d PGJ<sub>2</sub> in the cells at any time during our studies, indicating that at least 98% of this metabolite remained outside the cell. If 15d PGJ<sub>2</sub> is binding to PPAR-γ in RAW264.7 cells, it is either being reabsorbed or the levels needed to activate PPAR-γ are so low that they are below our 5 pg detection limit.

**TLR and Ca<sup>2+</sup> Synergy**—We have shown previously that incubating macrophages with LPS acts to prime them for enhanced eicosanoid production in response to the Ca<sup>2+</sup> agonist PAF (21, 28, 29). In that work, P388D<sub>1</sub> cells were primed with LPS prior to activation with PAF, creating an enhanced release of [3H]AA metabolites that was decreased in the presence of protein synthesis inhibitors ActD and CHX. This led to the hypothesis that TLR-4-induced protein synthesis, presumably COX-2, was responsible for priming the cells for a Ca<sup>2+</sup> burst, which would activate cPLA<sub>2</sub> to synthesize PGs.

In this study, we investigated TLR priming in RAW264.7 cells. Although the previous studies investigated either PGE<sub>2</sub> or total radiolabel release, we have now examined the complete eicosanoid spectrum. When primed with Kdo<sub>2</sub>-lipid A, GPCR agonists PAF and UDP stimulated eicosanoid production that was not enhanced. The transient Ca<sup>2+</sup> spike was sufficient to activate eicosanoid production, presumably through COX-1, but this pathway was additive with the TLR-4 pathway. On the other hand, Kdo<sub>2</sub>-lipid A appears to synergistically enhance the release of specific eicosanoids produced by ATP and ionomycin. Although the majority of PGs showed no significant change, the release of AA, COX-derived 11-HETE, and 5-LO products increased dramatically. The 5-LO product 5-HETE was enhanced by 20–40-fold, whereas the total AA released, i.e. the sum of all AA and eicosanoids, was enhanced 3–5-fold. This indicates that both cPLA<sub>2</sub> mediated AA release and 5-LO mediated products were enhanced.

Our results differ from the previous published work in that here we found no enhancement of PG production. This difference from P388D<sub>1</sub> cells is due in part to the fact that in the previous studies the enhancement was calculated under the assumption that TLR activation did not generate significant levels of PGE<sub>2</sub> within 1 h of activation. However, our results clearly demonstrate that in RAW264.7 cells TLR-4 activation leads to eicosanoid generation within this time frame, and if this is taken into account there is no significant enhancement of the PGs.

Furthermore, when ActD and CHX were used to inhibit protein synthesis, or BAY was used to inhibit NF-κB specifically, eicosanoid production via Kdo<sub>2</sub>-lipid A was completely shut down during the 1st h. However, the levels of AA were not affected. This confirms that eicosanoid production during this period is dependent upon new protein synthesis, presumably COX-2, and that this enzyme production requires NF-κB. Apparently the AA produced in response to Kdo<sub>2</sub>-lipid A activation cannot reach the existing pools of COX but can be used by newly synthesized COX. This could be due to the fact that without a Ca<sup>2+</sup> spike, cPLA<sub>2</sub> is brought to the membrane via PI(3) or ceramide 1-phosphate (C1P) (44, 45), which is located in specific subcellular organelles, whereas a Ca<sup>2+</sup> spike allows cPLA<sub>2</sub> to bind nonspecifically or to a different set of membranes.

In contrast to 60 min of Kdo<sub>2</sub>-lipid A, stimulation with ATP alone in the presence of protein synthesis inhibitors had only a small effect on eicosanoid release. Inhibition of NF-κB also had no significant effect on eicosanoid synthesis. Because ATP-induced eicosanoid production was complete within 10 min, it is not expected that protein synthesis would play a significant role in this pathway.

The total eicosanoid release of ATP-activated cells that were primed with Kdo<sub>2</sub>-lipid A was also diminished by the presence of ActD, CHX, and BAY. This was not surprising, in light of the fact that these inhibitors blunted ATP-stimulated eicosanoid release and completely inhibited Kdo<sub>2</sub>-lipid A eicosanoid production. However, the synergistic activation ratio was unchanged by these inhibitors, as well as by the NF-κB activation inhibitor 6-amino-4-(4-phenoxyphenylethylamino) quinazoline. This indicates that TLR-4 priming does not require the NF-κB-induced protein synthesis triggered by TLR-4 activation.

The separation of eicosanoid release enhancement from protein synthesis is bolstered by the results shown in Fig. 6. The levels of cPLA<sub>2</sub>, COXs, 5-LO, and FLAP do not change significantly during this time frame. The enhancement effect appears to be due to synergistic activation of cPLA<sub>2</sub> and the subsequent release of AA and LTs, whereas protein synthesis only affects COX metabolites. Because the phosphorylation levels and in vitro activity of cPLA<sub>2</sub> are not noticeably altered, changes in the components that translocate cPLA<sub>2</sub> to its membrane substrate are likely to play a significant role.

**Current Model of Eicosanoid Activation**—We have developed a working model that explains the eicosanoid profiles and priming characteristics demonstrated in RAW264.7 cells (Fig. 9). This model accounts for the data through the differential regulation of cPLA<sub>2</sub>, COX, and 5-LO.

The activity of cPLA<sub>2</sub> can be controlled by three possible mechanisms. First, the enzyme levels in the cell could be increased by gene up-regulation. There is evidence that this does not occur for cPLA<sub>2</sub> in macrophages (46, 47), and in our hands the level of this enzyme does not appear to change in response to various agonists. Second, the activity could be increased by phosphorylation of the enzyme. Phosphorylation of Ser-505 has been shown to increase cPLA<sub>2</sub> activity when studied in vitro (48); however, there is some question whether this mechanism is utilized in vivo to regulate activity, because in resting cells the enzyme exhibits some basal phosphorylation (46, 49). In this regard, our data demonstrate that Ser-505 is highly phosphorylated on cPLA<sub>2</sub> in basal RAW264.7 cells, and neither Kdo<sub>2</sub>-lipid A, ionomycin, nor ATP affects the in vitro activity. The third and most likely mechanism for macrophage regulation of cPLA<sub>2</sub> is through control of its translocation to membranes.

Under resting conditions, cPLA<sub>2</sub> is a soluble enzyme and must translocate to the membrane to reach its substrate and to produce AA. To date, translocation has been shown to be
increased by both changes in Ca\(^{2+}\) and phospholipids. Increases in cytosolic Ca\(^{2+}\) facilitate cPLA\(_2\) binding to phospholipids in membranes via its C-2 domain. Translocation can also be accomplished in a Ca\(^{2+}\)-independent fashion through an increase in specific membrane phospholipids. Six and co-workers (42, 43) have shown that PIP\(_2\) increases cPLA\(_2\) membrane affinity and activity. In addition to membrane binding effects, they also identified a potential PIP\(_2\) conformational change that increases specific activity of the enzyme. PIP\(_2\) generation has recently been linked with TLR activation (50, 51). Murayama and co-workers (44) have recently demonstrated a similar in vitro activation effect with C1P. Additionally, ceramide (52, 53) and diacylglycerol (54) have also been shown to increase cPLA\(_2\) membrane affinity. Localized concentrations of a number of specific phospholipid species could realistically facilitate translocation, and thus increase the activity of the cPLA\(_2\) enzyme.

The activities of the COX enzymes appear to be primarily controlled by expression. COX-1 is usually expressed constitutively, whereas COX-2 is typically found at low levels in resting cells but can be up-regulated by several hundredfold in response to certain agonists. Once expressed, both enzymes do not require Ca\(^{2+}\) or phosphorylation for activity. However, the enzymatic mechanism requires a tyrosine radical for activity that is easily quenched (3, 4), leading to its inactivation after a relatively small number of turnovers. This rapid inactivation naturally limits PG production in the absence of continual expression.

Similar to cPLA\(_2\), 5-LO appears to be controlled by a complex set of mechanisms. It contains a similar C-2 domain to cPLA\(_2\) that requires significant levels of Ca\(^{2+}\) for translocation to the membrane. This enzyme can also be activated by phosphorylation (1, 48). Additionally, the presence of FLAP is essential for productive in vivo activity, although its exact role remains unclear (5). The catalytic activity of 5-LO can be inhibited by nitric oxide produced by long term TLR activation (55). Using this information regarding cPLA\(_2\), COX, and 5-LO regulation, we shall describe our results parting terms of an integrated model for regulating eicosanoid production.

In response to PAF or UDP, a burst of Ca\(^{2+}\) raises cytosolic Ca\(^{2+}\) that increases specific activity of the enzyme. PIP\(_2\) generation also be accomplished in a Ca\(^{2+}\) elevate that leads to a more robust, longer lasting translocation of cPLA\(_2\) to the membrane. This is reflected by a 2–4-fold higher release of total AA-derived metabolites by ionomycin and ATP when compared with GPCR receptor agonists. In addition to increased cPLA\(_2\) activity, a sustained Ca\(^{2+}\) flux is sufficient to additionally activate 5-LO. In this case, the COX and 5-LO pathways are both active and generate PGs and LTs, respectively.

Short term Kdo\(_2\)-lipid A stimulation activates protein synthesis that begins to increase COX levels in 60 min. Because Kdo\(_2\)-lipid A does not induce Ca\(^{2+}\) release, it must activate cPLA\(_2\) by an alternative mechanism. Presumably this occurs by increasing the levels of PIP\(_2\) or C1P that sequester the enzyme to the membrane. Again, the 5-LO arm is not active because there is no Ca\(^{2+}\) change. This stimulation pathway produces a moderate level of primarily PG production.

The level of total eicosanoid production by either transient or sustained Ca\(^{2+}\) activation pales in comparison to long term Kdo\(_2\)-lipid A stimulation. Long term stimulation with Kdo\(_2\)-lipid A leads to significant protein synthesis, in particular COX-2; it would also allow for the significant changes in the levels of PIP\(_2\) or C1P, which could explain the increase in cPLA\(_2\) activity. Both of these factors would also explain the significant increase in the levels of PG released. Again, the lack of a Ca\(^{2+}\) increase means that only the PG arm of the pathway is active and thus the PG dominated eicosanoid profile.

Kdo\(_2\)-lipid A priming causes two dramatic changes in the RAW264.7 cell response to ATP. First, the total level of AA released, i.e. the sum of AA and all of the eicosanoids detected increase considerably. Second, PG levels are not enhanced, whereas leukotrienes are significantly enhanced. An increase in total eicosanoid production, including arachidonic acid, implies a corresponding change in cPLA\(_2\) activity. We have shown that the levels of cPLA\(_2\) and its in vitro activity do not seem to change during priming. TLR-4 activation also increases the mitogen-activated protein kinase pathways. However, we could not detect an increase in cPLA\(_2\) phosphorylation. Of course, some other mechanism...
for cPLA₂ activation may be involved. It is possible that the Ca²⁺ could be acting synergistically with PIP₂ or C1P to increase the levels of cPLA₂ at the surface. In vitro studies have shown that PIP₂ increases the specific activity of cPLA₂, which could indicate a potential mechanism for synergy.

The activation ratio of the 5-HETE is significantly greater than that for total AA production. This implies that the 5-LO pathway could account for the lack of enhancement in the PG levels; it is also possible that the levels of COX are increased as cPLA₂. Thus, it becomes clear that synergy requires a sustained increase in Ca²⁺ coupled to the non-protein synthesis portions of the Kdo₂-lipid A priming. The lack of synergy with UDP and PAF could also be explained if the COX levels are limited.

In summary, we have found that it is critical to track all eicosanoid products when characterizing agonist-induced cellular responses. This has allowed us to refine our understanding of the Kdo₂-lipid A priming of RAW264.7 cells and to discover new insights into the mechanism of synergy.
Synergistic Eicosanoid Production in Macrophages

50. Grkovich, A., Johnson, C. A., Buczynski, M. W., and Dennis, E. A. (2006) 
   *J. Biol. Chem.* **281**, 32978–32987

51. Kagan, J. C., and Medzhitov, R. (2006) *Cell* **125**, 943–955

52. Huwiler, A., Johansen, B., Skarstad, A., and Pfeilschifter, J. (2001) *FASEB J.* **15**, 7–9

53. Klapisz, E., Masliah, J., Bereziat, G., Wolf, C., and Koumanov, K. S. (2000) 
   *J. Lipid Res.* **41**, 1680–1688

54. Seeds, M. C., Nixon, A. B., Wykle, R. L., and Bass, D. A. (1998) *Biochim. 
   Biophys. Acta* **1394**, 224–234

55. Coffey, M. J., Phare, S. M., and Peters-Golden, M. (2000) *J. Immunol.* **165**, 
   3592–3598